Bariatric device-maker Apollo Endosurgery Inc. and biotech company Lpath Inc. have announced plans to merge under an arrangement that will see Apollo shareholders own about 95.8% of the combined company. Once the deal is final, Lpath will be renamed Apollo Endosurgery, Inc.
The combined company intends to apply for a listing on the NASDAQ global market under a new trading symbol. LPath’s stock was trading at $2.65 a share when the market...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?